US009408923B2

(12) **United States Patent**
Lin et al.

(10) **Patent No.: US 9,408,923 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF**

(71) Applicants: **AbGenomics International Inc.**, Dover, DE (US); **BioAlliance C.V.**, Alkmaar (NL)

(72) Inventors: **Rong-Hwa Lin**, Palo Alto, CA (US); **Shih-Yao Lin**, Taipei (TW); **Yu-Chi Hsieh**, New Taipei (TW); **Chiu-Chen Huang**, Taipei (TW)

(73) Assignees: **BioAlliance C.V.**, Alkmaar (NL); **AbGenomics International Inc.**, Dover, DE (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/742,621**

(22) Filed: **Jun. 17, 2015**

(65) **Prior Publication Data**

US 2016/0015830 A1 Jan. 21, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/137,799, filed on Dec. 20, 2013, now Pat. No. 9,089,614.

(60) Provisional application No. 61/785,027, filed on Mar. 14, 2013, provisional application No. 61/745,448, filed on Dec. 21, 2012.

(51) **Int. Cl.**

A61K 47/48	(2006.01)
C07D 241/36	(2006.01)
A61K 38/06	(2006.01)
A61K 31/404	(2006.01)
A61K 31/407	(2006.01)
C07D 295/192	(2006.01)
C07K 7/02	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 47/48715*** (2013.01); ***A61K 31/404*** (2013.01); ***A61K 31/407*** (2013.01); ***A61K 38/06*** (2013.01); ***A61K 47/48215*** (2013.01); ***A61K 47/48338*** (2013.01); ***A61K 47/48384*** (2013.01); ***A61K 47/48438*** (2013.01); ***A61K 47/48569*** (2013.01); ***A61K 47/48615*** (2013.01); ***C07D 241/36*** (2013.01); ***C07D 295/192*** (2013.01); ***C07K 7/02*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,816,567	A	3/1989	Cabilly et al.
5,545,806	A	8/1996	Lonberg et al.
5,545,807	A	8/1996	Surani et al.
5,569,825	A	10/1996	Lonberg et al.
5,625,126	A	4/1997	Lonberg et al.
5,633,425	A	5/1997	Lonberg et al.
5,661,016	A	8/1997	Lonberg et al.
5,750,373	A	5/1998	Garrard et al.
5,985,908	A	11/1999	Boger
6,060,608	A	5/2000	Boger
6,214,345	B1	4/2001	Firestone et al.
6,262,271	B1	7/2001	Boger
6,281,354	B1	8/2001	Boger
6,486,326	B2	11/2002	Boger
6,548,530	B1	4/2003	Boger
7,091,186	B2	8/2006	Senter et al.
7,223,837	B2	5/2007	De Groot et al.
7,553,816	B2	6/2009	Senter et al.
7,674,605	B2	3/2010	Lin et al.
7,754,681	B2	7/2010	Feng
7,982,017	B2	7/2011	Lin et al.
8,153,581	B2	4/2012	Kratz
8,309,093	B2	11/2012	Gudas et al.
8,394,607	B2	3/2013	Ebens, Jr. et al.
8,568,718	B2	10/2013	Lin et al.
9,089,614	B2	7/2015	Lin et al.
2006/0024317	A1	2/2006	Boyd et al.
2010/0124551	A1	5/2010	Lin et al.
2011/0301334	A1	12/2011	Bhakta et al.
2012/0282175	A1	11/2012	Carrigan et al.
2013/0177579	A1	7/2013	Lin et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	2357006	A2	8/2011
WO	WO-99/58572	A1	11/1999

(Continued)

OTHER PUBLICATIONS

Blencowe et al, Polym. Chem (2011) 2 p. 773-785.*

Al-Lazikani, B. et al. (Nov. 7, 1997). "Standard Conformations for the Canonical Structures of Immunoglobulins," Journal of Molecular Biology 273(4):927-948.

Bandgar, B.P. et al. (2003). "Highly Rapid and Direct Synthesis of Monoacylated Piperazine Derivatives from Carboxylic Acids Under Mild Conditions," Tetrahedron Letters 44: 3855-3858.

Blencowe, C.A. et al. (2011). "Self-Immolative Linkers in Polymeric Delivery Systems," Polym. Chem. 2:773-790.

Boerner, P. et al. (Jul. 1, 1991). "Production of Antigen-Specific Human Monoclonal Antibodies from in Vitro-primed Human Splenocytes," Journal of Immunology 147(1):86-95.

(Continued)

Primary Examiner — Maury Audet
Assistant Examiner — Fred Reynolds
(74) *Attorney, Agent, or Firm* — Morrison & Foerster LLP

(57) **ABSTRACT**

The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.

20 Claims, 7 Drawing Sheets